Business
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds. VivoSim’s liver predictive power was shown to be 87.5% for a set of challen
About this update from Vivosim Labs, Inc.
[{"type":"image","alt":"VivoSim Labs, Inc.","displaySize":"","headline":null,"caption":"VivoSim Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/6a88504001493c597ac71133a03d0f65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/drwxXtsrPrlixrLKdGN.xQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a88504001493c597ac71133a03d0f65","width":300,"height":54}},"lazy":false},{"type":"text","content":"SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds.","length":424,"tagName":"p"},{"type":"text","content":"VivoSim’s liver predictive power was shown to be 87.5% for a set of challenging liver toxicity cases – inclusive of classic cases of “liver tox misses” drugs with unforeseen liver toxicity found in clinical trials or drugs that were withdrawn from the market after liver toxicity issues emerged later. The platform identified correctly that 87.5% of the known liver-toxic drugs could be seen as liver toxic using NAMkind™ liver. This is known as the sensitivity of the platform, which at 87.5% is a world’s best. Importantly, the specificity was 100%, meaning that none of the compounds tested that are not liver toxic were incorrectly identified as having liver toxicity issues by the platform.","length":695,"tagName":"p"},{"type":"text","content":"VivoSim’s NAMkind™ liver model is a physical organoid wet lab model of liver made using cells from human donors. VivoSim is also developing what it believes will be industry-best in silico predictions of liver tox. Artificial intelligence (AI) models in VivoSim’s NAMkind™ services suite will be trained on extensive set of proprietary, real-world data from organoid models made from human donor cells, giving much richer and more extensive information than is possible with data from human clinical trials.","length":507,"tagName":"p"},{"type":"text","content":"VivoSim offers liver and intestinal toxicology ins...